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Fig. S1. The distribution of Sequence Ontology functional consequences of GWAS significant variant associations (p-
value ≤ 5×10-8). 
Fig. S2. Number of protein-coding genes in LD region. Shown above is a jittered line plot, where each point represents an
LD region, its position on the x-axis is the number of protein-coding genes found in the region, and its position on the y-




Fig. S3: Translational potential of GWAS disease associations across all MeSH root disease areas and mental disorders. 
The figure illustrates the results from GWAS studies, including LD regions, druggable genes in those regions, and 
compounds/drugs that have activity against the product of the druggable genes. In the penultimate row, the numbers of 
drugs that have an indication that is concordant (C) or discordant (D) with the GWAS phenotype are displayed. In the final
row, the number of cognate targets for the concordant or discordant drugs is shown. Note that for the purposes of the 
figure, a drug target is a single gene even if it is part of a complex that is targeted by the drug. Within each cell the values 
represent the number of unique entities. For example, the cells in the Associations row represent the number of unique 
rsids. However, some values can be replicated across the figure because a GWAS study may have researched several of 
the disease areas. Additionally, there is some non-additivity between consecutive rows, namely Druggable Gene Priority - 
Distance Rank and Drugs - Drug indication/Disease Phenotypes. In the case of the former, this is due to the same gene 
being further away from the associated variant in different studies, such that it falls into a different partition. For the later, 
this is due to missing indications for some of the drugs, such that concordance or discordance could not be assigned. The 
values in the row labels represent the unique number of items across the row. The estimated number of samples is the sum




Fig. S4. Translational potential of GWAS biomarker associations with relevance to disease across the all MeSH root 
disease areas and mental disorders The figure illustrates the results from GWAS studies, including LD regions, druggable 
genes in those regions, and compounds/drugs that have activity against the product of the druggable genes. In the 
penultimate row, the numbers of drugs that have an indication that is concordant (C) or discordant (D) with the GWAS 
phenotype are displayed. In the final row, the number of cognate targets for the concordant or discordant drugs is shown. 
Note that for the purposes of the figure, a drug target is a single gene even if it is part of a complex that is targeted by the 
drug. Within each cell, the values represent the number of unique entities. For example, the cells in the Associations row 
represent the number of unique rsids. However, some values can be replicated across the figure because a GWAS study 
may have researched several of the disease areas. Additionally, there is some non-additivity between consecutive rows, 
namely Druggable Gene Priority - Distance Rank and Drugs - Drug indication/Disease Phenotypes. In the case of the 
former, this is due to the same gene being further away from the associated variant in different studies, such that it falls 
into a different partition. For the later, this is due to missing indications for some of the drugs, such that concordance or 
discordance could not be assigned. The values in the row labels represent the unique number of items across the row. The 
estimated number of samples is the sum of all the cases involved in the respective studies.
Fig. S5. Density of variant coverage across the druggable genome. Data are shown for directly typed variants in major 
commercial arrays including the DrugDev array introduced in this manuscript and for all the 1000 genomes phase 3 sub-
populations (indicated at the top of each plot) with the super population group in brackets. EUR – European populations 
(GBR –British in England and Scotland, CEU – Utah Residents (CEPH) with Northern and Western Ancestry, FIN - 
Finnish in Finland, IBS - Iberian Population in Spain, TSI - Toscani in Italy). AMR – American populations (MXL - 
Mexican Ancestry from Los Angeles USA, PUR - Puerto Ricans from Puerto Rico, CLM - Colombians from Medellin, 
Colombia, PEL - Peruvians from Lima, Peru). EAS – East Asians (CHB - Han Chinese in Bejing, China, CHS - Southern 
Han Chinese, CDX - Chinese Dai in Xishuangbanna, China, JPT - Japanese in Tokyo, Japan, KHV - Kinh in Ho Chi Minh
City, Vietnam). SAS – South Asians (ITU - Indian Telugu from the UK, GIH - Gujarati Indian from Houston, Texas, PJL -
Punjabi from Lahore, Pakistan, STU - Sri Lankan Tamil from the UK, BEB - Bengali from Bangladesh). AFR – Africans 
(ASW - Americans of African Ancestry in SW USA, ACB - African Caribbeans in Barbados, YRI - Yoruba in Ibadan, 
Nigeria, ESN - Esan in Nigeria, MSL - Mende in Sierra Leone, GWD - Gambian in Western Divisions in the Gambia, 
LWK - Luhya in Webuye, Kenya)
 
Fig. S6. Density of variant coverage across the druggable genome. Data are shown for directly typed and tagged variants 
(at r2 ≥ 0.8) in major commercial arrays including the DrugDev array introduced in this manuscript and for all the 1000 
genomes phase 3 sub-populations (indicated at the top of each plot) with the super population group in brackets. EUR – 
European populations (GBR –British in England and Scotland, CEU – Utah Residents (CEPH) with Northern and Western
Ancestry, FIN - Finnish in Finland, IBS - Iberian Population in Spain, TSI - Toscani in Italy). AMR – American 
populations (MXL - Mexican Ancestry from Los Angeles USA, PUR - Puerto Ricans from Puerto Rico, CLM - 
Colombians from Medellin, Colombia, PEL - Peruvians from Lima, Peru). EAS – East Asians (CHB - Han Chinese in 
Bejing, China, CHS - Southern Han Chinese, CDX - Chinese Dai in Xishuangbanna, China, JPT - Japanese in Tokyo, 
Japan, KHV - Kinh in Ho Chi Minh City, Vietnam). SAS – South Asians (ITU - Indian Telugu from the UK, GIH - 
Gujarati Indian from Houston, Texas, PJL - Punjabi from Lahore, Pakistan, STU - Sri Lankan Tamil from the UK, BEB - 
Bengali from Bangladesh). AFR – Africans (ASW - Americans of African Ancestry in SW USA, ACB - African 
Caribbeans in Barbados, YRI - Yoruba in Ibadan, Nigeria, ESN - Esan in Nigeria, MSL - Mende in Sierra Leone, GWD - 
Gambian in Western Divisions in the Gambia, LWK - Luhya in Webuye, Kenya)
Fig. S7. Directly typed variant coverage of druggable genes in the 1000 genomes subpopulations. Coverage of the 
druggable gene set is represented as a proportion of 1000 genomes phase 3 variants (bi-allelic with maf ≥ 0.005) that are 
directly typed. Within each plot, a column represents a druggable gene and each row a genotyping array. The druggable 
genes are grouped according to their druggability tier, which is indicated by the color bar at the base of each plot. To aid 
visualization, the druggable genes are further sorted within each tier on their median coverage across all the arrays, and 
the genotyping arrays are sorted based on their median coverage of the druggable genome across all the 1000 genomes 
sub populations, with the super population group in parentheses at the top of each section. EUR – European populations 
(GBR –British in England and Scotland, CEU – Utah Residents (CEPH) with Northern and Western Ancestry, FIN - 
Finnish in Finland, IBS - Iberian Population in Spain, TSI - Toscani in Italy). AMR – American populations (MXL - 
Mexican Ancestry from Los Angeles USA, PUR - Puerto Ricans from Puerto Rico, CLM - Colombians from Medellin, 
Colombia, PEL - Peruvians from Lima, Peru). EAS – East Asians (CHB - Han Chinese in Bejing, China, CHS - Southern 
Han Chinese, CDX - Chinese Dai in Xishuangbanna, China, JPT - Japanese in Tokyo, Japan, KHV - Kinh in Ho Chi Minh
City, Vietnam). SAS – South Asians (ITU - Indian Telugu from the UK, GIH - Gujarati Indian from Houston, Texas, PJL -
Punjabi from Lahore, Pakistan, STU - Sri Lankan Tamil from the UK, BEB - Bengali from Bangladesh). AFR – Africans 
(ASW - Americans of African Ancestry in SW USA, ACB - African Caribbeans in Barbados, YRI - Yoruba in Ibadan, 
Nigeria, ESN - Esan in Nigeria, MSL - Mende in Sierra Leone, GWD - Gambian in Western Divisions in the Gambia, 
LWK - Luhya in Webuye, Kenya). Note that all of the arrays contained content that could not be mapped to the 1000 
genomes phase 3 (see fig. S10).
 Fig. S8. Directly typed variant coverage of druggable genes in the 1000 genomes subpopulations. Coverage of the 
druggable gene set is represented as a proportion of 1000 genomes phase 3 variants (bi-allelic with maf ≥ 0.005) that are 
directly typed or tagged (at r2 ≥ 0.8). Within each plot, a column represents a druggable gene and each row a genotyping 
array. The druggable genes are grouped according to their druggability tier, which is indicated by the color bar at the base 
of each plot. To aid visualization, the druggable genes are further sorted within each tier on their median coverage across 
all the arrays, and the genotyping arrays are sorted based on their median coverage of the druggable genome across all the 
1000 genomes subpopulations, with the super population group in parentheses at the top of each section. EUR – European
populations (GBR –British in England and Scotland, CEU – Utah Residents (CEPH) with Northern and Western Ancestry,
FIN - Finnish in Finland, IBS - Iberian Population in Spain, TSI - Toscani in Italy). AMR – American populations (MXL -
Mexican Ancestry from Los Angeles USA, PUR - Puerto Ricans from Puerto Rico, CLM - Colombians from Medellin, 
Colombia, PEL - Peruvians from Lima, Peru). EAS – East Asians (CHB - Han Chinese in Bejing, China, CHS - Southern 
Han Chinese, CDX - Chinese Dai in Xishuangbanna, China, JPT - Japanese in Tokyo, Japan, KHV - Kinh in Ho Chi Minh
City, Vietnam). SAS – South Asians (ITU - Indian Telugu from the UK, GIH - Gujarati Indian from Houston, Texas, PJL -
Punjabi from Lahore, Pakistan, STU - Sri Lankan Tamil from the UK, BEB - Bengali from Bangladesh). AFR – Africans 
(ASW - Americans of African Ancestry in SW USA, ACB - African Caribbeans in Barbados, YRI - Yoruba in Ibadan, 
Nigeria, ESN - Esan in Nigeria, MSL - Mende in Sierra Leone, GWD - Gambian in Western Divisions in the Gambia, 
LWK - Luhya in Webuye, Kenya). Note that all of the arrays contained content that could not be mapped to the 1000 
genomes phase 3 (see fig. S10). 
 
Fig. S9. Criteria for manual evaluation of the concordance/discordance of GWAS phenotypes and drug indications and 
side effects. 
 
Fig. S10. Proportion of content in various commercial arrays mapped to the 1000 genomes phase 3 set of variants. The 
numbers in the bars show the total content on the array. The black bar is the DrugDev array introduced in this manuscript. 
The numbers after some of the array names indicate version numbers. The dashed line is to aid comparison of the Drug 
Dev array with the other arrays on the plot
Table S1: The druggable genome. Druggable genes, their locations and druggability priority, as well as the number of 
times each gene has overlapped an LD region surrounding a significant GWAS association (P ≤ 5×10-8) are indicated 
along with the type of molecule that binds to each of the druggable genes. Provided as an Excel file.
Table S2. Pfam-A domain content in three tiers of druggable genes. Summarized are counts of the 15 most frequent Pfam-
A domains in genes assigned to each of the three tiers. Pfam domains with measured small molecule interactions are 
marked with asterisks. Tiers 1 and 2 incorporated domain types belonging to well-studied drug target classes, such as 
GPCRs, kinases, and ligand-gated ion channels. The domain composition of Tier 3 reflects enrichment for secreted and 
extracellular proteins, including constituents of the extracellular matrix, immunoglobulins, and leucine-rich repeats found 
on membrane-bound toll-like receptors.  
Tier 1 Tier 2 Tier 3
Pfam-A # Pfam-A # Pfam-A #
Pkinase * 194 Pkinase * 81 7tm_1 * 113
7tm_1 * 119 7tm_1 * 41 V-set 74
Pkinase_Tyr * 100 Trypsin * 16 Collagen 61
p450 * 47 Ion_trans * 13 Ion_trans * 61
fn3 32 Y_phosphatase * 11 LRR_8   59
Ion_trans * 30 PI3_PI4_kinase * 9 Pkinase * 55
Neur_chan_LBD * 28 Hormone_recep * 9 Ig_2 55
Neur_chan_memb 28 zf-C4 9 Trypsin * 52
SH2 * 25 Pro_isomerase * 9 I-set 50
Hormone_recep * 25 Neur_chan_LBD * 8 EGF_CA 49
zf-C4 25 SH2 * 8 Ig_3 44
ig 23 Pkinase_C 8 EGF 42
ABC_tran * 23 Neur_chan_memb 8 7tm_4 41
ANF_receptor * 22 Bromodomain * 7 Kelch_1 40
Pkinase_C 21 Pkinase_Tyr * 6 Lectin_C 39


















































1 asthma Acute asthma | Acute 
exacerbation of chronic 
obstructive airways 
disease | Bronchial asthma
| Chronic obstructive 
pulmonary disease | Left 
ventricular failure - cardiac
failure - cardiac asthma | 
Reversible airways 
obstruction | Routine 
maintenance therapy in 




448153 1 2 1











1 bone density Prevention of skeletal 
related events in advanced
malignancy involving bone
| Treatment of bone loss 
associated with hormone 
ablation in prostate cancer















Carcinoma of breast | 













1 - 2 2 1





Acute ischaemic stroke: 
fibrinolytic treatment| 
Thrombolysis in acute 
myocardial infarction| 
Thrombolysis of occluded 
central venous access 
devices | Thrombolytic 












inadequate response to 
MTX | Active progressive 
rheumatoid arthritis | 
Moderate to severe plaque
rs1799964 2110246
3
1036 2 13 4
psoriasis: when other 
treatment is inappropriate 
| Moderate/severe 
ulcerative colitis: when 
other treatment is 
inappropriate | 
Rheumatoid arthritis when 
inadequate response to 
DMARDs incl. 
methotrexate | Severe 
active rheumatoid arthritis 
| Severe ankylosing 
spondylitis in adults if 
conventional therapy 
inadequate | Treatment of 
active & progressive 
psoriatic arthritis when 
DMARD inadequate | 















adequately controlled by 
individual components | 
Prinzmetal's angina | 
Prophylaxis of chronic 
stable angina pectoris | 















Angina | Angina pectoris - 
prophylaxis of acute 
attacks | Angina pectoris - 
treatment of acute attacks
| Congestive heart failure 
(adjunct) | Intracoronary 
use during angioplasty and
to prevent/relieve coronary
spasm | Left ventricular 
failure | Prophylaxis of 
angina pectoris | 
Treatment of angina 
pectoris | Treatment of 
unresponsive LVF, either 
post MI or of various 




7988 1 2 1















lowering therapy adjunct 
to diet | Homozygous 
familial 
hypercholesterolaemia 
(adjunct to statin therapy) 
| Homozygous familial 
hypercholesterolaemia: 











(hyperlipidaemia type IIa): 
Adjunct to diet | Primary 
hypercholesterolaemia: 
lipid lowering therapy 
adjunct to diet














when statin is 
contraindicated or not 
tolerated | Primary 
hypercholesterolaemia: 
lipid lowering therapy 
adjunct to diet | Reduction 

















Hypercalcaemia due to 
























Active juvenile idiopathic 
arthritis (unresp to 
NSAIDs) in comb with MTX 
| Active juvenile idiopathic 
arthritis when inadequate 
response to NSAIDs | 
Rheumatoid arthritis 
(unresp to DMARD/TNF 
inhib.) in comb with 
methotrexate | 
Rheumatoid arthritis when 












inadequate response to 
MTX | Active progressive 
rheumatoid arthritis | 
Moderate to severe plaque
psoriasis: when other 
treatment is inappropriate 
| Moderate/severe 
ulcerative colitis: when 
other treatment is 
rs2596565 2453267
7
190015 24 145 27
inappropriate | 
Rheumatoid arthritis when 
inadequate response to 
DMARDs incl. 
methotrexate | Severe 
active rheumatoid arthritis 
| Severe ankylosing 
spondylitis in adults if 
conventional therapy 
inadequate | Treatment of 
active & progressive 
psoriatic arthritis when 
DMARD inadequate | 
Treatment of active 
Crohn's disease
ABCC8 Glimepiride Small 
molecul
e
1 type II 
diabetes 
mellitus
Type 2 diabetes (NIDDM) 
not controlled by 




4860 - 5802 3 5 3
ABCC8 Glipizide Small 
molecul
e
1 type II 
diabetes 
mellitus
Non insulin dependent 




4860 - 5802 3 5 3
ABCC8 Glyburide Small 
molecul
e
1 type II 
diabetes 
mellitus
Type 2 diabetes (NIDDM) 
not controlled by 
diet,weight loss & exercise
alone 








4860 - 5802 3 5 3
ABCC8 Nateglinide Small 
molecul
e
1 type II 
diabetes 
mellitus
Control of type-2 diabetes 




4860 - 5802 3 5 3
ABCC8 Repaglinide Small 
molecul
e
1 type II 
diabetes 
mellitus
Control of type-2 diabetes 
(NIDDM) with metformin if 
metformin inadequate | 
Type 2 diabetes (NIDDM) 
not controlled by 




4860 - 5802 3 5 3
KCNJ11 Glimepiride Small 
molecul
e
1 type II 
diabetes 
mellitus
Type 2 diabetes (NIDDM) 
not controlled by 




1224 - 1306 1 5 3
KCNJ11 Glipizide Small 
molecul
e
1 type II 
diabetes 
mellitus
Non insulin dependent 




1224 - 1306 1 5 3
KCNJ11 Glyburide Small 
molecul
e
1 type II 
diabetes 
mellitus
Type 2 diabetes (NIDDM) 
not controlled by 
diet,weight loss & exercise
alone 








1224 - 1306 1 5 3
KCNJ11 Nateglinide Small 
molecul
e
1 type II 
diabetes 
mellitus
Control of type-2 diabetes 




1224 - 1306 1 5 3
KCNJ11 Repaglinide Small 
molecul
e
1 type II 
diabetes 
mellitus
Control of type-2 diabetes 
(NIDDM) with metformin if 
metformin inadequate | 
Type 2 diabetes (NIDDM) 
not controlled by 










1 type II 
diabetes 
mellitus
Combination treatment of 
Type 2 diabetes with 
insulin | Control of type-2 
diabetes if 
metformin+sulphonylurea 
therapy is inadequate | 
Monotherapy for type2 
diabetes if overweight and 
metformin inappropriate | 
Oral combination 


















Epilepsy - combination of 
both partial and tonic-














Moderate to severe 















Gout   (prophylaxis) | 





























6233 - 8364 1 1 - 2 1 - 2
PDE4D Roflumilast Small 
molecul
e












Epilepsy - grand mal | 
Epilepsy - partial seizures |
Epilepsy - tonic-clonic 
seizures | Prophylaxis of 
manic-depressive illness 











to clomifene citrate | 
Ovarian stimulation before 
in vitro fertilisation | 
Stimulation of 
spermatogenesis with 




12316 1 1 1




Acute ischaemic stroke: 
fibrinolytic treatment| 
Thrombolysis in acute 
myocardial infarction | 
Thrombolysis of occluded 
central venous access 
devices | Thrombolytic 


























4 asthma Alternative to exercise 
stress in thallium-201 
myocardial imaging | 
Ischemic stroke: 
Secondary prevention 
(with/without aspirin) | 
Secondary prevention of 
ischaemic stroke | 




etic heart valve: 
prophylaxis (+oral 












4 resting heart 
rate
Mild - moderate dementia 
in Alzheimer's disease | 
Mild - moderate dementia 













4 heart rate Myasthenia gravis | 
Paralytic ileus | Paroxysmal
supra-ventricular 
tachyarrhythmias | Post 
operative distention| Post 
operative urinary retention
| Reversal of residual 
competitive 















62368 1 3 1
Table S3. Illustrative examples of mapping SNPs curated in the GWAS catalog to LD intervals containing targets of licensed and clinically used drugs. The genes 
encoding the drug targets are listed using Human Genome Nomenclature Catalogue designation. Drug names and indications are from First Data bank. GWAS SNPs 
are listed according to Refseq number, and physical distances are in base pairs (bp). Curation code refers to the correspondence between the treatment indication and 
GWAS disease or trait association. Some examples show treatment indication rediscoveries (curation codes 1 and 2). For many of these, the drug target gene is the 
sole occupant of the LD interval defined by the GWAS SNP. Examples come from a variety of disease areas and, for some diseases (such as type 2 diabetes and 
rheumatoid arthritis), multiple target rediscoveries are noted.  Examples of rediscoveries of mechanism of action (curation code 3) and mechanism-based side effects 
(curation code 4) are also seen.
Table S4. Summary of the physical properties of LD regions. The properties were stratified by the manually curated concordance/discordance group to which 
compounds targeting the druggable genes within them are assigned.




LD region length (bp) # genes in 
LD region
# druggable 
genes in LD 
region
Unassigned - 0 1348 29020 [9531-62570] 1 [1-3] 79320 [39740-217100] 2 [1-9] 1 [1-3]
Concordant 1-4,34 2100 29020 [9489-39160] 1 [1-1] 50260 [26440-75500] 1 [1-2] 1 [1-1]
Discordant 5-6 1523 72620 [22650-178900] 3 [1-7] 137900 [63490-5e+05] 5 [2-17] 1 [1-4]
Mixed 54 582 39260 [10760-52190] 1 [1-2] 116800 [59720-229300] 3 [1-4] 1 [1-2]
Remaining 7-9 797 18260 [8416-86080] 1 [1-6] 128700 [23860-320700] 5 [2-16] 2 [1-5]
